cyrilzakka/clinical-trials huggingface dataset:
ADHD PreSMA Response Inhibition Therapy

ADHD children have abnormal inhibitory control, meaning they have trouble stopping themselves from doing something they should not do. This ability to control involves an area in the brain called the pre-supplementary motor area (pre-SMA). Scientists have previously shown that the pre-SMA is abnormal in ADHD patients. In this study, we will use Transcranial Magnetic Stimulation (TMS) to stimulate the pre-SMA and determine the effects on measures that are related to inhibitory control.

ADHD children (ages 12-17 years) will be recruited. Cognitive testing and basic anatomic brain MRI will be performed during visit 1. During visit 2, baseline TMS-based physiologic measures will be obtained. Children will also complete a behavioral task (stop signal task) while electroencephalography (EEG) data is collected. After these baseline measures, two trains of Intermittent Theta Burst Stimulation (iTBS) will be delivered. (Intermittent Theta Burst Stimulation is a form of repetitive TMS.) The first train of iTBS will be randomized to sham vs. active in a 1:1 ratio. The second train of iTBS is active for all participants. After both iTBS trains are completed, repeat TMS-based measures, stop signal task and EEG data will be collected again. Visit 3 will be one week after visit 2. Visit 3 is a virtual computer-based visit to assess for any potential side effects.

Eligibility Criteria:
Inclusion Criteria:

1. ADHD diagnosis
2. Ages 12-17 years
3. Stimulant use is allowed but must be discontinued 24 hours prior to and during days of TMS visit

Exclusion Criteria:

1. Medical conditions contraindicated or associated with altered TMS risk profile, including history of intracranial pathology, epilepsy or seizure disorders, traumatic brain injury, brain tumor, stroke, intellectual disability, cerebral palsy, neurodegenerative conditions, hearing impairment, metallic objects in the head or any other serious medical condition
2. Presence of any implanted medical devices (e.g., ports, shunts, stimulators, cochlear implants)
3. For biological females who are post-menarche, current pregnancy based on urine pregnancy test.
4. Baseline problem of hearing impairment or chronic tinnitus
5. Any clinically significant finding on brain MRI
6. History of DSM-5 conduct disorder, major depressive disorder, bipolar disorder, obsessive compulsive disorder, anxiety disorder, psychotic disorder
7. Non-stimulant medication(s) for ADHD (e.g., alpha2 adrenergic agonist, atomoxetine, tricyclics)
8. Neuroleptic/antipsychotic medication(s)
9. Inability to undergo MRI
10. Active suicidality, history of suicidality, or high risk for suicide as assessed by a study physician
11. Substance abuse or dependence within the past year, based on 1) separate screening process of asking parent/guardian and participant, and 2) positive urine drug screen. Exception will be made for positive urine drug screen due to prescribed ADHD medication
The Effects of Laparoscopic Guided Transversus Abdominis Plane (TAP) Block in Sleeve Gastrectomy Procedure.

Sleeve gastrectomy is the most performed bariatric procedure worldwide. Postoperative pain management is a challenging issue. In this trial, the investigators aimed to explore the effects of laparoscopic guided transversus abdominis plane (TAP) block on postoperative pain management in patient those were performed laparoscopic sleeve gastrectomy.

TAP block is a regional anesthesia technique which could be performed easily especially by laparoscopy and are used in various surgical procedures. In that technique, blockade of the plane between internal oblique muscle and transversus abdominis muscle is performed by infiltration of local anesthesics drugs. Therefore , reduction of postoperative pain could be lead to decrease in postoperative complications.

Eligibility Criteria:
Inclusion Criteria:

* patients between 18-65
* undergo Laparoscopic sleeve gastrectomy

Exclusion Criteria:

* Bupivacaine allergy
* having chronic pain or taking pain management
* ASA ( The American Society of Anesthesiologists Physical Classification System) Class 4 or
* Patients who were performed additional procedures including cholecystectomy, hiatal hernia repair or abdominal hernia repair
Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients

This study aimed to to compare the conventional transarterial chemoembolization (cTACE) with chemoembolization using doxorubicin drug eluting beads (DEB-TACE) for the treatment of hepatocellular carcinoma regarding short term efficacy and safety in first 3 months after embolization

This prospective case control was conducted at the Department of Tropical Medicine and HCC Clinic, Ain Shams University Hospitals (Cairo, Egypt), The patients were divided according to the line of treatment into 2 groups:

1. Group (I): Twenty-five patients underwent Chemoembolization with Drug eluting beads.
2. Group (II): Twenty-five patients underwent conventional Chemoembolization (cTACE)

The total number of procedures was 77 sessions (37 sessions of TACE with beads and 40 sessions of conventional TACE).Post-procedure follow up:

Schedule of follow up:

All included patients were checked at:

1. One week after the procedure to detect early post chemoembolization complications and Patients were subjected to Liver function tests, Kidney function tests, complete blood count and Abdominal Ultrasound.
2. One and four months after the maneuver.

Patients were subjected to the following in each visit:

1. Complete History taking
2. Thorough clinical examination
3. Laboratory Investigations including:

   1. Liver function tests
   2. Kidney function tests
   3. CBC
   4. Serum alpha-fetoprotein.
4. Triphasic pelvi-abdominal CT Follow up imaging was performed at the first and fourth months after embolization and every 3 months thereafter. Repeated embolization was scheduled "on demand" basis, if there was residual viable tumor deemed unsuitable for radiofrequency ablation or surgery.

Eligibility Criteria:
Inclusion Criteria:

* Confirmed diagnosis of HCC according to the European association of study of liver diseases
* Early stage HCC (Stage A), using the Barcelona Clinic Liver Cancer (BCLC) staging system, (single or 3 nodules \< 3cm PS 0) whenever curative measures were contraindicated and BCLC stage B (intermediate HCC).
* Patent portal vein and its main branches
* Informed consent from all participants before enrollment in the study.

Exclusion Criteria:

* Patients with Child class C according to Child classification (BCLC D).
* Patients with diffuse HCC (non-measurable lesion).
* Patients with thrombosis of main portal vein or one of its main branches (BCLC C).
* Patients with extra hepatic invasion.
* patients refused to participate in the study
Aggressive Behavior Induced by Selective Serotonin Reuptake Inhibitors (SSRIs) During the First Month of Treatment

SSRIs are the first line of therapy for anxiety and depressive disorders and for many other clinical diagnoses. One of the most disturbing side effects that is observed is a tendency towards aggressiveness among patients receiving medications from this group, mainly during the first month of therapy. Aggressive behavior tends to occur in some individuals but not in others. In some sub-groups of people, personality and character traits might make a person more prone to aggressive behavior.

In this study the investigators try to estimate the tendency towards aggressive behavior in patients prescribed to a medication from the SSRI group. By using a comparative computer simulation they hope to be able to detect delicate changes and to maybe get some clues of the personalities prone to aggressive behavior in the future.

Selective serotonin reuptake inhibitors (SSRIs) became the first line therapy for anxiety and depressive disorders and for many other clinical diagnoses. One of the most disturbing side effects that is observed is a tendency towards aggressiveness among patients receiving medications from this group, mainly during the first (one month) period of therapy. Aggressive behavior tends to occur in some individuals but not in others. Until now most of the cases and reports in the literature demonstrate the extreme events of aggressive behavior. These personality or any other character traits that are more prone to develop aggressiveness have not been studied and it is not clear if this side effect manifests itself just in the extreme rare cases or if it is a more common phenomenon that occurs in a wider group of people.

In this study we try to estimate the tendency towards aggressive behavior of patients prescribed to a medication of the SSRI group. By using a comparative computer simulation we hope to be able to detect more delicate changes and maybe to get some clues of the personalities prone to aggressive behavior in the future.

Eligibility Criteria:
Inclusion Criteria:

* Age above 18 years
* Instructed by his/her family physician to start taking a medicine in the SSRI group

Exclusion Criteria:

* According to the family practitioner's record: under SSRI, SNRI, or NRI treatment during the previous 3 months or at the time of entry into the study.
* Diagnosed with schizophrenia or active psychosis or impaired judgment
* Anti-social personality disorder
* Drug use or alcohol abuse
Pharmacologically Triggered Migraine Without Aura and Neuroimaging

Migraine is a highly disabling disorder affecting 14% of the general population Worldwide and ranked as the 6th most debilitating disease worldwide by the WHO. One of the most fundamental questions of migraine, which remains to be elucidated, is the mechanism behind the generation of migraine attacks.

The investigators will use calcitonin gene-related peptide (CGRP) and sildenafil as pharmacological triggers of migraine, combined with advanced neuroimaging techniques, to investigate the attack initiating pathophysiology.

Both substances have previously been administered to healthy participants and migraine without aura patients, inducing headache and migraine-like-attacks.

The investigators hope to contribute with novelty to the current understanding of the migraine pathophysiology and development of more efficient treatment of migraine.


Eligibility Criteria:
Inclusion Criteria:

* Age between 18 and 50 years
* Weight: 50-100 kg
* Diagnosis of migraine without aura (patient group only)
* Attacks of migraine without aura at least once every second month (patient group only)

Exclusion Criteria:

* Inconsistent laterality of headache
* History or family history of migraine (healthy subject group only)
* Tension-type headache more than one day per month on average (healthy subject group only)
* Tension-type headache to such a degree that the episodic migraine diagnosis is no longer fulfilled
* Any other primary headache disorder
* Daily intake of medication (apart from oral contraceptives)
* Intake of any medication less than 4 half-lives before study start
* Daily smoking
* Pregnant or breastfeeding women
* Headache 48 h prior to study day
* Hypertension on the study day (systolic BP\>150 mmHg or diastolic BP\> 100 mmHg)
* Hypotension on the study day (systolic BP\<90 mmHg or diastolic BP\<50 mmHg)
* History of any cardiovascular disease including cerebrovascular disease
* Any disorder, that is deemed ineligible for participation by the study physicians
* Contraindications of MRI
* No use of safe contraception (women of fertile age only)
Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis

The purpose of this study is to determine if the screening of nasopharyngeal carcinoma using plasma Epstein-Barr virus DNA analysis would result in the detecting NPC cases at earlier stages and improve survival.

Epstein-Barr virus (EBV) infection is an important etiological factor for nasopharyngeal carcinoma (NPC). In a pilot study, we have shown that the analysis of Epstein-Barr virus (EBV) DNA in blood can detect early and asymptomatic NPC. However, it is unlcear if NPC screening can improve the prognosis of the screened NPC subjects.

20,000 male subjects aged from 40 to 62 will be recruited because the incidence of NPC is higher in this target group. Twenty millilitres of venous blood will be collected from each subject at enrolment for plasma EBV DNA analysis.

Subjects who have initial positive results for plasma EBV DNA will have another testing at approximately 4 weeks. Subjects who have persistently positive results for the two plasma EBV DNA analyses will be investigated using nasal endoscopic examination and MRI of the nasopharynx.

After the initial screening, all participants will be phone interviewed yearly to update their cancer status.

A second round of screening will be carried out at 3 to 5 years after the initial round of screening. Subjects will be screened with plasma EBV DNA as in the first round of screening. Subjects with initial positive results will be retested and those with persistently positive results will be investigated using nasal endoscopic examination and MRI of the nasopharynx.

Eligibility Criteria:
Inclusion Criteria:

* age 40 to 62 years
* ethnic Chinese
* male

Exclusion Criteria:

* history of nasopharyngeal carcinoma
* currently having a malignant disease
* active autoimmune disease
* HIV infection
* on systemic steroid treatment
* on immunosuppressant treatment
Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease

This study examines the long term Safety Follow-up of first patients vaccinated with AD02.

Patients who have received AD02 during AFF002 and AFF004A will be observed.

Eligibility Criteria:
Inclusion Criteria:

* participation in AFF002 and AFF004A

Exclusion Criteria:

* no vaccination with AD02
Prospective Registry of Mobilization-, Routine- and Outcome Data of Intensive Care Patients

Registry database of intensive care patients. These data comprises of routine data including mobilization data and follow up assessments.

Registry database of intensive care patients. These data comprises of routine data including mobilization data and follow up assessments.

The database is supposed to help quality improvement as well as

Eligibility Criteria:
Inclusion Criteria:

* Intensive care unit stay \> 24 hours

Exclusion Criteria:

-
Plantar Plate Repair for Treatment of Floating Toe: Must we Associate it to Weil Osteotomy?

The aim of this study is to assess if isolated Weil osteotomy for floating toe grade II or III provides results that are not inferior to those obtained with the Weil osteotomy associated with plantar plate repair.


Eligibility Criteria:
Inclusion Criteria:

* 18 years old, minimum
* ability to understand treatment and recovery
* floating toe

Exclusion Criteria:

* age less than 18 years old at the moment of recruiting
* patients who are not able to understand treatment and recovery
* intraoperative diagnosis of plantar plate injury grade 0, I or IV in Nery's classification
* secondary surgery
Zambia SiVET MMR Tdap-IPV

Participants will receive vaccination for measles, mumps, and rubella (MMR) and tetanus, diphtheria, pertussis, and inactivated polio (Tdap-IPV). The study schedule design is to simulate a vaccine efficacy trial to see if single women can participate in studies that mimic actual HIV vaccine studies.

This study will evaluate if women at high risk for HIV infection residing in Lusaka, Zambia and Ndola, Zambia are willing to participate and can be retained in future HIV vaccine trials. 150 women will be enrolled that are either sex workers or single women that were identified at infant vaccination clinics (at risk due to a recent pregnancy indicating unprotected sexual contact outside of marriage or cohabitation). Two licensed vaccines will be administered as proxies for HIV vaccine administration. The clinic and laboratory procedures will simulate HIV vaccine trial procedures and will therefore inform recruitment and retention strategies and HIV incidence among high risk women in future HIV vaccine trials.

Eligibility Criteria:
Inclusion Criteria:

* At high risk of HIV, defined by occupation (female sex workers) or recent delivery (single mothers)
* Planning to stay in Lusaka or Ndola for at least 12 months
* Willing to undergo HIV testing, counseling and receive HIV test results Able and willing to provide adequate locator information for tracking purposes, and willing to be contacted by the study staff
* Willing and able to provide adequate locator information and willing to be contacted by phone if available or home visit by study staff.
* Willing to answer questions on HIV risk factors, and if infected, questions related to the route and timing of exposure
* Willing and able to return for follow-up visits
* Willing and able to provide informed consent
* Willing to undergo pregnancy testing and use an injectable, implant or intrauterine device (IUD) from screening until four months after the last vaccination during the study

Exclusion Criteria:

* HIV-1/2 infection
* Pregnant or intending to become pregnant during the study
* History of severe allergic reaction to any substance including eggs, gelatin, and neomycin
* Any clinically significant acute illness or chronic medical condition that is considered progressive, or in the opinion of the investigator, makes the volunteer unsuitable for participation in the study
* Immunosuppressive therapy
* Women who opt out of HIV counseling and testing services provided by the clinic
* Women who have any condition that in the opinion of the Investigator or designee, would preclude provision of informed consent, or otherwise interfere with achieving the study objectives
* Participation in another clinical trial unless approved by the Principal Investigator and the International AIDS Vaccine Initiative (IAVI)
* Recent receipt of an investigational blood product or vaccine
* Failure of assessment of understanding
Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of Topical Administration of 1% GPB Cream in Patients With Primary Axillary Hyperhidrosis.

The aim of this study is to investigate the efficacy and safety of 1% GPB cream after 4 weeks of treatment compared with placebo with a sufficient number of patients to obtain statistically significant results, and to assess the long-term safety of 1% GPB cream.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of severe primary axillary hyperhidrosis with a HDSS score of 3 or 4
* At least 50 mg of sweat production in each axilla measured gravimetrically at room temperature and at a humidity consistent with the normal climate in that area over a period of 5 minutes (patients should have acclimatized to that room for at least 30 minutes)
* Men and women aged 18 to 65 years at the time of informed consent with a body mass index of 18-32 kg/m2
* Able to comply with protocol requirements, including overnight stays, blood sample collections as defined in the protocol subjects
* Willing and able to provide written informed consent

Exclusion Criteria:

* Known allergy to any of the components in the investigational product.
* Hypersensitivity against glycopyrrolate
* Secondary hyperhidrosis, for example, hyperhidrosis that is secondary to other underlying diseases including hyperthyroidism, lymphoma and malaria, climacteric hyperhidrosis.
* Previous surgical treatment of hyperhidrosis including sympathectomy, surgical debulking of the sweat glands, subcutaneous tissue curettage and ultrasonic surgery.
* Botulinum toxin treatment in the prior 4 months.
* Angle closure glaucoma or its precipitation (narrow angle).
* Mycotic, other skin infections and other dermal disorder including infection at anticipated application sites in either axilla.
* Any condition or situation that, in the investigator's or sub-investigator's opinion, may interfere with the patient's participation in the study;
A Feasibility Study Evaluating a Novel Mask (Nasal Reservoir Cannula)

This study evaluates the addition of a novel mask (nasal reservoir cannula) to a standard nasal cannula during supplemental oxygenation for the treatment of hospitalized pediatric patients with hypoxemia due to severe pneumonia. Half of patients (Group A) will receive oxygen for 1 hour using a novel mask (nasal reservoir cannula) plus standard nasal cannula (Period 1), followed by a 1-hour period of continued use of the standard nasal cannula delivery (Period 2). Half of patients (Group B) will receive oxygen for 1 hour using a standard nasal cannula (Period 1), followed by a 1-hour period of continued use of the novel mask (nasal reservoir cannula) plus standard nasal cannula (Period 2).

Pneumonia is the leading infectious cause of death among children less than 5 years of age. Hypoxemia is a major fatal complication of pneumonia, and the risk of death increases with increasing severity of hypoxemia. Improving oxygen delivery and extending oxygen supplies to children with hypoxemia due to severe pneumonia could reduce mortality in resource-limited settings.

Global Good has developed a low cost oxygen mask (nasal reservoir cannula) to more efficiently deliver oxygen to the pediatric patient by increasing dead space to recapture a portion of expelled oxygen using the spatial distribution of the nasal reservoir cannula volume and length of surface seal. This nasal reservoir cannula fits over a standard nasal cannula (also termed prong). The system is designed to reduce administered oxygen to deliver an equal or higher fraction of inspired oxygen (FiO2) per oxygen delivered (L/min) compared with a standard nasal cannula alone.

Eligibility Criteria:
Inclusion Criteria:

1. Age ≥ 1 and ≤ 6 years.
2. Severe pneumonia based on WHO criteria
3. SpO2 ≥ 85% and \< 94% by pulse oximetry on room air
4. Hospital admission based on clinician judgment
5. Written informed consent from parent(s)/guardian(s) of subjects must be obtained before any study procedure is performed
6. Body weight ≥ 8 kg and ≤ 26 kg

Exclusion Criteria:

1. Hypercapnia (pCO2 \> 55 mm Hg or 7.32 kPa) on room air
2. Acidosis / lactic acidosis (pH \<7.20 and/or lactate \>6 mg/dL) on room air
3. SpO2 \< 85% or ≥ 94% by pulse oximetry on room air
4. SICK score \> 2.4
5. Hemoglobin \< 7 g/dL
6. Facial abnormalities or trauma precluding use of mask and nasal prongs.
7. Requirement of intubation or non-invasive or invasive positive-pressure ventilation
8. Suspected or known pneumothorax
9. Body weight \< 8 kg or \> 26 kg
10. Hemodynamic instability based on clinician judgment
11. SpO2 \< 90% by pulse oximetry on oxygen, measured at the end of the enrollment and before initiation of Period 1